The price of Chemours Company (NYSE: CC) closed at $26.41 in the last session, up 1.50% from day before closing price of $26.02. On the day, 1336335 shares were traded.
Ratios:
We take a closer look at CC’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.17 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 21.13. For the most recent quarter (mrq), Quick Ratio is recorded 1.00 and its Current Ratio is at 1.54. In the meantime, Its Debt-to-Equity ratio is 5.83 whereas as Long-Term Debt/Eq ratio is at 5.69.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BMO Capital Markets on April 09, 2024, Upgraded its rating to Outperform and sets its target price to $34 from $19 previously.
On March 05, 2024, UBS Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $37 to $21.
BMO Capital Markets Downgraded its Outperform to Underperform on February 29, 2024, whereas the target price for the stock was revised from $45 to $19.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 09 ’23 when Newman Mark bought 7,661 shares for $34.63 per share. The transaction valued at 265,300 led to the insider holds 266,955 shares of the business.
Scarborough Alvenia sold 5,125 shares of CC for $165,537 on Jun 09 ’23. The SVP Corp Communications & CBO now owns 13,890 shares after completing the transaction at $32.30 per share. On Jun 08 ’23, another insider, Abbott Matthew S, who serves as the SVP, Chief Enterprise Transfor of the company, sold 8,912 shares for $34.20 each. As a result, the insider received 304,790 and left with 29,869 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 0.65 while its Price-to-Book (P/B) ratio in mrq is 5.32.
Stock Price History:
Over the past 52 weeks, CC has reached a high of $39.05, while it has fallen to a 52-week low of $15.10.
Shares Statistics:
A total of 148.59M shares are outstanding, with a floating share count of 147.02M. Insiders hold about 1.20% of the company’s shares, while institutions hold 76.44% stake in the company.
Earnings Estimates
The company has 6 analysts who recommend its stock at the moment. On average, analysts expect EPS of $0.15 for the current quarter, with a high estimate of $0.29 and a low estimate of $0.09, while EPS last year was $0.98. The consensus estimate for the next quarter is $0.81, with high estimates of $1.1 and low estimates of $0.62.
Analysts are recommending an EPS of between $4 and $1.62 for the fiscal current year, implying an average EPS of $2.39. EPS for the following year is $3.87, with 7 analysts recommending between $5.2 and $2.85.
Revenue Estimates
According to 3 analysts, the current quarter’s revenue is expected to be $1.35B. It ranges from a high estimate of $1.36B to a low estimate of $1.33B. As of the current estimate, Chemours Company’s year-ago sales were $1.46B, an estimated decrease of -7.90% from the year-ago figure.
A total of 6 analysts have provided revenue estimates for CC’s current fiscal year. The highest revenue estimate was $5.98B, while the lowest revenue estimate was $5.77B, resulting in an average revenue estimate of $5.88B. In the same quarter a year ago, actual revenue was $6.03B, down -2.50% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $6.27B in the next fiscal year. The high estimate is $6.52B and the low estimate is $6.02B. The average revenue growth estimate for next year is up 6.70% from the average revenue estimate for this year.
